Literature DB >> 16466168

[Clinical efficacy of treatment for regulating Pi and protecting Xin in treating patients after coronary artery bypass grafting and its effect on patients' quality of life].

Xin-Min Ruan1, Wei Jiang, Yu Lin.   

Abstract

OBJECTIVE: To evaluate the clinical efficacy of treatment for regulating Pi and protecting Xin (abbr. as CHM) and its effect on quality of life (QOL) in patients after coronary artery bypass grafting (CABG).
METHODS: One hundred and six patients, who were planned to undergo CABG were assigned into two groups, the 51 patients in the control group were treated with conventional Western medicinal treatment (WM) and the 55 patients in the experimental group were treated by WM with additional medication of CHM constituted mainly by modified Huxin Recipe. The changes of symptoms and heart function were observed and the patients' QOL was evaluated by SF-36 Scale.
RESULTS: After being treated for 3 months, the total scores of symptoms in the experimental group was significantly improved in comparing with that in the control group (P < 0.01), the clinical efficacy on symptoms of TCM and improvement of heart function were superior to those in the control group (P < 0.05) respectively. The scores in terms of pain, vitality, role of emotion, mental health, health transition of patients in the experimental group according to SF-36 scale were significantly higher than those in the control group (P < 0.05 or P < 0.01).
CONCLUSION: Treatment for regulating Pi and protecting Xin by modified Huxin Recipe can improve the recovery process of patients after CABG, elevate patients' heart function, symptoms and QOL.

Entities:  

Mesh:

Year:  2006        PMID: 16466168

Source DB:  PubMed          Journal:  Zhongguo Zhong Xi Yi Jie He Za Zhi        ISSN: 1003-5370


  2 in total

1.  Shenzhu Guanxin Recipe Granules () for Improving Exercise Tolerance in Patients with Stable Angina (SERIES Trial): A Protocol of Multicenter, Randomized, Double-Blind, Placebo Parallel Controlled Clinical Trial.

Authors:  Shuai Mao; Dan-Ping Xu; Xiao-Jing Dang; Winny Li; Huan-Lin Wu
Journal:  Chin J Integr Med       Date:  2018-10-17       Impact factor: 1.978

2.  A multicentre randomized clinical trial on efficacy and safety of huxin formula in patients undergoing percutaneous coronary intervention.

Authors:  Huan-Lin Wu; Yun-Fei Wang; Jun-Zhe Li; Min-Zhou Zhang; Xiao-Gang Sheng; Xia Wang; Song Li; Qiu-Xiong Chen; Xiao-Qing Li; Ai-Hua Ou; Xin-Min Ruan
Journal:  Evid Based Complement Alternat Med       Date:  2014-05-26       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.